MARKET

HALO

HALO

Halozyme Thrp
NASDAQ
49.62
-0.04
-0.08%
Closed 16:20 06/13 EDT
OPEN
49.32
PREV CLOSE
49.66
HIGH
49.91
LOW
48.86
VOLUME
1.36M
TURNOVER
0
52 WEEK HIGH
53.00
52 WEEK LOW
32.78
MARKET CAP
6.32B
P/E (TTM)
20.53
1D
5D
1M
3M
1Y
5Y
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
NASDAQ · 1d ago
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
NASDAQ · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Halozyme (HALO), Arbutus Biopharma (ABUS) and Annexon Biosciences (ANNX)
TipRanks · 4d ago
Weekly Report: what happened at HALO last week (0603-0607)?
Weekly Report · 4d ago
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Agios Pharmaceuticals Inc shares soared 29.13% in the last week. Verint Systems Inc. Shares zoomed 22.40% after the company reported better-than-expected Q1 financial results. Novavax shares gained 21.54% after FDA voted to recommend updated vaccines.
Benzinga · 4d ago
Halozyme Therapeutics: The Story Brightens
Seeking Alpha · 6d ago
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
JP Morgan analyst Matthew Boss downgraded the rating for Vail Resorts, Inc. From Neutral to Underweight. Exxon Mobil Corporation was also downgraded from Buy to Hold. Morgan Stanley downgraded Gen Digital Inc. And cut the price target from $28 to $27.
Benzinga · 6d ago
Halozyme downgraded at Piper Sandler despite guidance raise
Healthcare Halozyme downgraded at Piper Sandler despite guidance raise. Halozyme Therapeutics, Inc. (HALO) increased its revenue and earnings outlook for 2024. The biotech's stock rose to a new 52-week high on Thursday after an EU patent win for its Enhanze drug delivery technology.
Seeking Alpha · 6d ago
More
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Webull offers Halozyme Therapeutics, Inc. stock information, including NASDAQ: HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.